Skip to main content
Erschienen in: Uro-News 12/2023

07.12.2023 | Stoßwellentherapie | Fortbildung

Was tun bei Induratio penis plastica?

Konservative Behandlungsoptionen im Überblick

verfasst von: Prof. Dr. med. Frank Christoph, Prof. Dr. med. Mark Schrader

Erschienen in: Uro-News | Ausgabe 12/2023

Einloggen, um Zugang zu erhalten

Auszug

Pathophysiologische Grundlagen, diagnostische Möglichkeiten und evidenzbasierte konservative Behandlungsoptionen: Was praktisch tätige Urologinnen und Urologen zum Thema Induratio penis plastica im täglichen Handeln wissen müssen. …
Literatur
1.
Zurück zum Zitat Schwarzer U et al. The prevalence of Peyronies's disease. Results of a large survey. BJU international 2001;88:727-30 Schwarzer U et al. The prevalence of Peyronies's disease. Results of a large survey. BJU international 2001;88:727-30
2.
Zurück zum Zitat De la Peyronie F. Sur quelques obstacles, qui s'opposent à l'éjaculation naturelle de la semence. Mémoires de l'Académie royale de médecine, Paris 1743;1:425-34 De la Peyronie F. Sur quelques obstacles, qui s'opposent à l'éjaculation naturelle de la semence. Mémoires de l'Académie royale de médecine, Paris 1743;1:425-34
3.
Zurück zum Zitat Arafa M et al. The prevalence of Peyronie's disease in diabetic patients with erectile dysfunction. Int J Impot Res 2007;19:213-7 Arafa M et al. The prevalence of Peyronie's disease in diabetic patients with erectile dysfunction. Int J Impot Res 2007;19:213-7
4.
Zurück zum Zitat Tal R et al. Peyronie's disease following radical prostatectomy: incidence and predictors. J Sex Med. 2010;7:1254-61 Tal R et al. Peyronie's disease following radical prostatectomy: incidence and predictors. J Sex Med. 2010;7:1254-61
5.
Zurück zum Zitat Mulhall J et al. Subjective and objective analysis of the prevalence of Peyronie's disease in population of men presenting with erectile dysfunction. J Urol 2004;171:2350-3 Mulhall J et al. Subjective and objective analysis of the prevalence of Peyronie's disease in population of men presenting with erectile dysfunction. J Urol 2004;171:2350-3
6.
Zurück zum Zitat Hellstrom W et al. Bother and distress associated with Peyronie's disease: validation of the Peyronie's disease questionnaire. J Urol 2013;190:627-34 Hellstrom W et al. Bother and distress associated with Peyronie's disease: validation of the Peyronie's disease questionnaire. J Urol 2013;190:627-34
7.
Zurück zum Zitat Nehra A et al. Peyronie's disease: AUA guideline. J Urol 2015;194:745-53 Nehra A et al. Peyronie's disease: AUA guideline. J Urol 2015;194:745-53
9.
Zurück zum Zitat Paulis G et al. Recent pathophysiological aspects of Peyronie's disease: Role of free radicals, rationale, and therapeutiv implications for antioxidant treatment - literature review. Adv Urol 2017; Article ID 4653512 Paulis G et al. Recent pathophysiological aspects of Peyronie's disease: Role of free radicals, rationale, and therapeutiv implications for antioxidant treatment - literature review. Adv Urol 2017; Article ID 4653512
10.
Zurück zum Zitat Devine C et al. Proposal: Trauma as the cause of the Peyronie's lesion. J Urol 1997:157:285-90 Devine C et al. Proposal: Trauma as the cause of the Peyronie's lesion. J Urol 1997:157:285-90
11.
Zurück zum Zitat Mitsui Y et al. Molecular mechanisms and risk factors related to the pathogenesis of Peyronie's disease. Int J Mol Sci 2023;24:10133 Mitsui Y et al. Molecular mechanisms and risk factors related to the pathogenesis of Peyronie's disease. Int J Mol Sci 2023;24:10133
12.
Zurück zum Zitat Liu R et al. Reciprocal regulation of TGF-β and reactive oxygen species: A perverse cycle for fibrosis. Redox Biol 2015;6:565-77 Liu R et al. Reciprocal regulation of TGF-β and reactive oxygen species: A perverse cycle for fibrosis. Redox Biol 2015;6:565-77
13.
Zurück zum Zitat Schreiber B et al. Percutaneous radiation therapy of peyronies's disease with 137cesium. Urologe A 1978;17:228-31 Schreiber B et al. Percutaneous radiation therapy of peyronies's disease with 137cesium. Urologe A 1978;17:228-31
14.
Zurück zum Zitat Safarinejad M et al. Comparison of Vitamin E and propionyl-L-carnitine, separately or in combination in patients with early chronic Peyronie's disease: a double-blind, randomized, placebo controlled study. J Urol 2007;178:1398-403 Safarinejad M et al. Comparison of Vitamin E and propionyl-L-carnitine, separately or in combination in patients with early chronic Peyronie's disease: a double-blind, randomized, placebo controlled study. J Urol 2007;178:1398-403
15.
Zurück zum Zitat Weidner W et al. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo controlled, randomized study. Eur Urol 2005;47:530-6 Weidner W et al. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo controlled, randomized study. Eur Urol 2005;47:530-6
16.
Zurück zum Zitat Carson C et al. Potassium paraaminobenzoate for the treatment of Peyronie's disease: is it effective? Tech Urol 1997;3:135-9 Carson C et al. Potassium paraaminobenzoate for the treatment of Peyronie's disease: is it effective? Tech Urol 1997;3:135-9
17.
Zurück zum Zitat Chung E et al. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med 2011;8:1472-7 Chung E et al. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med 2011;8:1472-7
18.
Zurück zum Zitat Özturk U et al. Effects of sildenafil treatment on patients with Peyronie's disease and erectile dysfunction. Ir J Med Sci 2014;183:449-53 Özturk U et al. Effects of sildenafil treatment on patients with Peyronie's disease and erectile dysfunction. Ir J Med Sci 2014;183:449-53
19.
Zurück zum Zitat Spirito L et al. Daily low-dose tadalafil may reduce the penile curvature progression rate in patients with acute Peyronie's disease: a retrospective comparative analysis. Int J Impot Res 2022; Spirito L et al. Daily low-dose tadalafil may reduce the penile curvature progression rate in patients with acute Peyronie's disease: a retrospective comparative analysis. Int J Impot Res 2022;
20.
Zurück zum Zitat Desanctis P et al. Steroid injection therapy for Peyronie's Disease: a 10-year summary and review of 38 cases. J Urol 1967;97:114-6 Desanctis P et al. Steroid injection therapy for Peyronie's Disease: a 10-year summary and review of 38 cases. J Urol 1967;97:114-6
21.
Zurück zum Zitat Levine L et al. Treatment of Peyronie's disease with intralesional verapamil treatment. J Urol 1997;158:1395-9 Levine L et al. Treatment of Peyronie's disease with intralesional verapamil treatment. J Urol 1997;158:1395-9
22.
Zurück zum Zitat Gelbard M et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 2013;190:199-207 Gelbard M et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 2013;190:199-207
23.
Zurück zum Zitat Lipshultz L et al. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double-blind, randomized, placebocontrolled, phase III studies. BJU Int 2015;116:650-6 Lipshultz L et al. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double-blind, randomized, placebocontrolled, phase III studies. BJU Int 2015;116:650-6
24.
Zurück zum Zitat Salam A et al. Treatment of Peyronie's disease by extracorporal shockwave therapy: evaluation of our preliminary results. J Endurol 1999;13:549-52 Salam A et al. Treatment of Peyronie's disease by extracorporal shockwave therapy: evaluation of our preliminary results. J Endurol 1999;13:549-52
25.
Zurück zum Zitat Gruenwald I et al. Low-intensity extracorporeal shock wave therapy - a novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy. J Sex med 2012;9:259-64 Gruenwald I et al. Low-intensity extracorporeal shock wave therapy - a novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy. J Sex med 2012;9:259-64
26.
Zurück zum Zitat Lu Z et al. Low-intensity Extracorporeal Shock Wave Treatment Improves Erectile Function: A Systematic Review and Meta-analysis. Eur Urol 2017;71:223-33 Lu Z et al. Low-intensity Extracorporeal Shock Wave Treatment Improves Erectile Function: A Systematic Review and Meta-analysis. Eur Urol 2017;71:223-33
27.
Zurück zum Zitat Clavijo R et al. Effects of Low-Intensity Extracorporeal Shockwave Therapy on Erectile Dysfunction: A Systematic Review and Meta-Analysis. J Sex Med 2017;14:27-35 Clavijo R et al. Effects of Low-Intensity Extracorporeal Shockwave Therapy on Erectile Dysfunction: A Systematic Review and Meta-Analysis. J Sex Med 2017;14:27-35
28.
Zurück zum Zitat Palmieri A et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease. Eur Urol 2009;56:363-70 Palmieri A et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease. Eur Urol 2009;56:363-70
29.
Zurück zum Zitat Palmieri A et al. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl 2012;35:190-5 Palmieri A et al. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl 2012;35:190-5
30.
Zurück zum Zitat Hatzichristodoulou G et al. Extracorporeal shock wave therapy in Peyronie's disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med 2013;10:2815-21 Hatzichristodoulou G et al. Extracorporeal shock wave therapy in Peyronie's disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med 2013;10:2815-21
31.
Zurück zum Zitat Wang X et al. Updated recommendations on the therapeutic role of extracorporeal shock wave therapy for peyronie's disease: systematic review and meta-analysis. BMC Urology 2023;23:145-56 Wang X et al. Updated recommendations on the therapeutic role of extracorporeal shock wave therapy for peyronie's disease: systematic review and meta-analysis. BMC Urology 2023;23:145-56
32.
Zurück zum Zitat Raheem AA et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie's disease. BJU Int 2010;106:1178-80 Raheem AA et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie's disease. BJU Int 2010;106:1178-80
33.
Zurück zum Zitat Joseph J et al. Outcomes of RestoreX Penile Traction Therapy in men with Peyronie‘s Disease: Results from open label and Follow-up Phases. J Sex Med 2020;17:2462-71 Joseph J et al. Outcomes of RestoreX Penile Traction Therapy in men with Peyronie‘s Disease: Results from open label and Follow-up Phases. J Sex Med 2020;17:2462-71
34.
Zurück zum Zitat Haney NM et al. The Effect of adjunct mechanical traction on penile length in men undergoing primary treatment for Peyronie‘s Disease: A systematic review and meta-analysis. Urology 2018;122:110-15 Haney NM et al. The Effect of adjunct mechanical traction on penile length in men undergoing primary treatment for Peyronie‘s Disease: A systematic review and meta-analysis. Urology 2018;122:110-15
Metadaten
Titel
Was tun bei Induratio penis plastica?
Konservative Behandlungsoptionen im Überblick
verfasst von
Prof. Dr. med. Frank Christoph
Prof. Dr. med. Mark Schrader
Publikationsdatum
07.12.2023
Verlag
Springer Medizin
Erschienen in
Uro-News / Ausgabe 12/2023
Print ISSN: 1432-9026
Elektronische ISSN: 2196-5676
DOI
https://doi.org/10.1007/s00092-023-5854-0

Weitere Artikel der Ausgabe 12/2023

Uro-News 12/2023 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.